Our merger with Aceragen is a key development in our goal to help patients with rare diseases get more from life.Learn More
Idera’s merger with Aceragen means a focus on bringing novel therapies to patients with pulmonology and rheumatology diseases that typically have no available treatment.Learn More
Idera’s TLR9 agonist may have potential to improve outcomes when used in combination with checkpoint inhibitors and other immune activators.Learn More
Keep up with what’s happening at Idera Pharmaceuticals.
DURHAM, N.C. and EXTON, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (Nasdaq: ACGN) a… Read more
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq… Read more
EXTON, Pa. and DURHAM, N.C. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more